The Cancer Organoids project at The Wellcome Sanger Institute involves the derivation, culture, banking and genetic validation of organoid cell lines produced from tumour samples taken from patients during surgical resection. The main aim of this project is to produce high quality, validated organoid models that reflect the cellular and genetic heterogeneity of prevalent human cancers. 

The Technology consists of:

• 230+ high quality, validated organoid models that reflect the cellular and genetic heterogeneity of prevalent human cancer
• Developed as part of Project Gro (https://www.sanger.ac.uk/collaboration/organoids-projectgro/) and Human Cancer Model Initiative (HCMI) aiming to derive and genetically characterise organoid cell models from prevalent human carcinomas to produce high quality organoid models suitable for a vast range of downstream scientific research.
• Patient-derived next-generation organoid cancer models were derived from cancer tumour samples taken during surgical resection, expanded and cryobanked.
• Each model has passed strict quality controls to ensure successful culturing.
• Available organoids models include: colon, oesophageal, breast, ovarian, pancreatic, gastric, mesothelial; the derivation is still ongoing.
• Sanger continues to submit organoids to ATCC for distribution to the scientific community.
• The Wellcome Sanger Institute is offering non-exclusive licences on these cell lines, subject to resolution of third party IP issues. Please contact us to express your interest.